Merck, amid pneumococcal vaccine race with Pfizer, suffers FDA delay for key pediatric use

In its next-generation pneumococcal vaccine race with Pfizer, Merck hopes to gain a key edge with a pediatric approval for Vaxneuvance.

But now comes a potentially costly delay as the FDA has extended its deadline for a regulatory decision to July 1.